Search results below include Worst Pills, Best Pills Newsletter Articles where your
selected drug is a secondary subject of discussion.
Public Citizen’s Health Research Group has designated amiodarone as Limited Use because long-term use of this drug can cause many types of adverse effects that can range from mild to life threatening. The drug should be used only when other therapies are ineffective or cannot be tolerated.
Extended-release niacin is approved by the FDA to reduce elevated cholesterol levels and to reduce the risk of recurrent, nonfatal heart attacks in patients with histories of previous heart attacks and elevated cholesterol levels. Learn why we just changed the designation of niacin extended-release tablets from Limited Use to Do Not Use.
Statins have long been a mainstay of treatment for patients with high LDL (“bad” cholesterol) and cardiovascular disease. In this article, we explain why you should avoid combining a nonstatin cholesterol-lowering dug with a statin.
A new study casts serious doubt on the usefulness of long-popular niacin products to treat or prevent cardiovascular disease.
The article discusses the reasons why we have categorized JUVISYNC as a DO NOT USE drug.
Find out why you should not use any of the three recently-approved diabetes drugs known as "gliptins".
This article lists 355 drugs with names that are often confused with similar-sounding drug names. Find out what you can do to prevent getting the wrong drug.
This article lists more than 60 prescription drugs that can interact with calcium channel blocking drugs such as amlodipine (NORVASC),diltiazem (CARDIZEM, DILACOR XR TIAZAC)or nifedipine (PROCARDIA)to either cause toxicity or to lessen the effectiveness of the calcium channel blocking drugs. Included in the lists are a number of drugs that we list in Worst Pills, Best Pills as DO NOT USE or LIMITED USE drugs. The article also explains the different kinds of toxicity that can ensue from these interactions.
The article discusses the adverse drug interactions between either of two widely-prescribed macrolide antibiotics, erythromycin (as in ERYTHROCIN) and clarithromycin (BIAXIN)and more than 40 other drugs that are listed in a table in the article. It also describes the nature of the adverse interactions that can occur.
This article explains how to understand the International Normalized Ratio (INR), a test applied to a sample of a patient’s blood to determine how “thin” it is when you are using the blood thinner COUMADIN (warfarin). In addition, the article lists more than 50 drugs or dietary supplements that can interact harmfully with COUMADIN to cause the blood to be too thin (abnormal bleeding) or not thin enough which could result in lessening the effect of COUMADIN in stopping blood clot formation.
Not only does this study find that consumer drug ads are not educational, it also says that the ads may oversell the benefits of the drugs and could put the public health in danger. For example, of the 24 drugs included in this advertising study, seven are listed as Do Not Use in Worst Pills, Best Pills publications. You should not rely on direct-to-consumer television advertisements as a source of drug information.
Assume that any new symptom you develop after starting a new drug may be caused by the drug. If you develop a new symptom after starting atorvastatin or other statins (such as nightmares), report it to your doctor. The drug may be responsible.
We are concerned about any new drug but are particularly concerned about the use of ZETIA together with statins.
We can think of no medical reason why you should be taking Caduet unless you are being treated satisfactorily with doses of amlodipine and atorvastatin that are available as Caduet. If you have not been tried on more effective drugs for high blood pressure such as diuretics or beta-blockers, amlodipine is a poor choice.
Rosuvastatin (CRESTOR) became the sixth cholesterol lowering "statin" drug on the U.S. There is no medical reason for you to be taking rosuvastatin when there are three safer and more effective statins, in terms of reducing cardiovascular events, on the market.
The following editorial, by Health Letter Editor Dr. Sidney Wolfe, appeared in the December issue of Pharmacoepidemiology and Drug Safety. Ultimately, the cost for such notification should be borne by the pharmaceutical company making the dangerous drug. Pharmacists and/or physicians, if the latter have record access, should be reimbursed for doing the company’s work. In addition, the FDA should be given new legislative authority to impose mandatory drug recalls with an enforceable withdrawal schedule governing the level and rapidity of recall and patient notification.